The 5-HT(1A) receptor and its ligands: Structure and function

Progress in Drug Research

Volumn 52, Issue , 1999, Pages 103-165

  Olivier, Berend ^a,b   Soudijn, Willem ^c   Van Wijngaarden, Ineke ^c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Solvay Pharmaceuticals Inc   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

5 HT(1A) receptor; 5 HT(1A) receptor ligands; Aminotetralins; Anxiety; Aporphines; Aryl oxyalkylamines; Arylpiperazines; Depression; Drug discrimination; Ergolines; Feeding; G protein; Indolylalkylamines; Serotonergic behaviour; Serotonin; Sexual behaviour; Structure affinity activity relationships; Temperature regulation

Indexed keywords

LIGAND; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; SEROTONIN 1 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY NEUROSIS; CHIMERA; COGNITIVE DEFECT; DEPRESSION; HUMAN; MOLECULAR BIOLOGY; MOLECULAR CLONING; MUTANT; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; ANIMAL; BRAIN; DRUG EFFECT; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BRAIN; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 0032587432     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0348-8730-4_3     Document Type: Review

References (285)

1. Erspamer V.: Arch. Exp. Pathol. Pharmacol. 196, 336-390 (1940).
2. Rapport M.M.: J. Biol. Chem. 180, 961-969 (1949).
3. Erspamer V. and Asero N.: Nature 169, 800-801 (1952).
4. Bertacinni G. and Chieppa S.: Lancet 1, 881 (1960).
5. Farthing M.J.G.: Scand. J. Gastroenterol. 26, 92-100 (1991).
6. Grahame-Smith D.G.: Quart. J. Med. 67, 459-466 (1988).
7. Twarag B.M. and Page I.H.: Am. J. Physiol. 174, 157-161 (1953).
8. Wooley D.W. and Shaw E.: Proc. Natl. Acad. Sci. 40, 228-231 (1954).
9. Steinbush H.W.M.: Neurosci. 4, 557-618 (1981).
10. Peroutka S.J. and Snyder S.H.: Mol. Pharmacol. 16, 687-695 (1979).
11. Jacobs B.L. and Azmitia E.C.: Physiol. Rev. 72, 165-229 (1992).
12. Törk I.: Ann. NY Acad. Sci. 600, 6-35 (1990).
13. Molliver M.E., Berger U.V., Mamounas L.A., Molliver D.C., O'Hearn E. and Wilson M.A.: Ann. NY Acad. Sci. 600, 640-664 (1990).
14. Holstege G.: Progr. Brain Res. 87, 307-412 (1991).
15. Holstege J.C., in: G. Holstege, R. Bandler and C. Saper (eds.): The Emotional Motor System. Elsevier, Amsterdam 1996, 159-182.
16. Pazos A. and Palacios J.M.: Brain Res. 346, 205-230 (1985).
17. Vergé D., Daval G., Marcikiewicz M., Patey A., El Mestikawy S., Gozlan H. and Hamon M.: J. Neurosci. 6, 3474-3482 (1986).
18. Gardier A.M., Malagrié I., Trillat A.C., Jacquot C. and Artigas F.: Fundam. Clin. Pharmacol. 10, 16-27 (1996).
19. Bosker F.J., De Winter T.Y.C.E., Klompkamers A.A. and Westenberg H.G.M.: J. Neurochem. 66, 2546-2555 (1996).
20. Chopin P., Moret C. and Briley M.: Pharmacol. Ther. 62, 385-405 (1994).
21. Hrdina P.D., Foy B., Hepner A., Summers R.J.: J. Pharmacol. Exp. Therap. 252, 410-418 (1990).
22. Pedigo N.W., Yamamura H.I. and Nelson D.L.: J. Neurochem. 36, 220-226 (1981).
23. Middlemiss D.N. and Fozard J.R.: Eur. J. Pharmacol. 90, 151-153 (1983).
24. Gozlan H., El Mestikawy S., Pichat L., Glowinski J. and Hanson M.: Nature 304, 140-142 (1983).
25. Pompeiano M., Palacios J.M. and Mengod G.: J. Neurosci. 12, 440-453 (1992).
26. Miquel M.C., Doucet E., Boni C., El Mestikawy S., Matthiessen L., Daval G., Vergé D. and Hamon M.: Neurochem. Int. 19, 453-465 (1991).
27. Chalmers D.T. and Watson S.J.: Brain Res. 561, 51-60 (1991).
28. Riad M., El Mestikawy S., Vergé D., Gozlan H. and Hamon M.: Neurochem. Int. 19, 413-423 (1991).
29. Radja F., Daval G., Hamon M. and Vergé D.: J. Neurochem. 58, 1338-1346 (1992).
30. Vergé D., Daval G., Patey A., Gozlan H., El Mestikawy S. and Hamon M.: Eur. J. Pharmacol. 113, 463-464 (1985).
31. Weissmann-Nanopoulos D., Mach E., Magre J., Demassey Y. and Pujol J.-F.: Neurochem. Int. 7, 1061-1072 (1985).
32. Sotelo C., Cholley B., El Mestikawy S., Gozlan H. and Hamon M.: Eur. J. Neurosci. 2, 1144-1154 (1990).
33. Lima L., Laporte A.-M., Gaymard C., Spedding M., Mocaër E. and Hamon M.: J. Neural Transmission 104, 1059-1075 (1997).
34. Sundaram H., Turner J.D. and Strange P.G.: J. Neurochem. 65, 1909-1916 (1995).
35. Newman-Tancredi A., Conte C., Chaput C., Verrièle L. and Millan M.J.: Neuropharmacology 36, 451-459 (1997).
36. Khawaja X., Evans N., Reilly Y., Ennis C. and Minchin M.C.W.: J. Neurochem. 64, 2716-2726 (1995).
37. Khawaja X., Ennis C. and Minchin M.C.W.: Life Sci 60, 653-665 (1997).
38. Khawaja X.: Brain Res. 673, 217-225 (1995).
39. Gozlan H., Thibault S., Laporte A.M., Lima L. and Hamon M.: Eur. J. Pharmacol. (Mol. Pharmacol. sect.) 288, 173-186 (1995).
40. Hall H., Lundkvist C., Halldin C., Farde L., Pike V.W., McCarron J.A., Fletcher A., Cliffe I.A., Barf T., Wikström H. and Sedvall G.: Brain Res. 745, 96-108 (1997).
41. Burnet P.W., Eastwood S.L. and Harrison P.J.: Neurochem. Int. 30, 565-574 (1997).
42. Pike V.W., McCarron J.A., Lammertsma A.A., Fletcher S.P., Poole K., Grasby P.M., Malizia A., Cliffe I.A., Fletcher A. and Bench C.J.: Eur. J. Pharmacol. 283, R1-R3 (1995).
43. Osman S., Lundkvist C., Pike V.W., Halldin C., McCarron J.A., Swahn C.-G., Ginovart N., Luthra S.K., Bench C.J. and Grasby P.M.: Nuclear Medicine Biol. 23, 627-634 (1996).
44. Pike V.W., McCarron J.A., Lammertsma A.A., Osman S., Hume S.P., Sargent P.A., Bench C.J., Cliffe I.A., Fletcher A. and Grasby P.M.: Eur. J. Pharmacol. 301, R5-R7 (1996).
45. Zhuang Z.-P., Kung M.-P., Mu M., Kung H.F.: J. Med. Chem. 41, 157-166 (1998).
46. Kobilka B.K., Frielle T., Collins S., Yang-Feng T., Kobilka T.S., Francke U., Lefkowitz R.J. and Caron M.G.: Nature 329, 75-79 (1987).
47. Fargin A., Raymond J.R., Lohse M.J., Kobilka B.K., Caron M.G. and Lefkowitz R.J.: Nature 335, 358-360 (1988).
48. Albert P.R., Zhou Q.-Y., Van Tol H.H.M., Bunzow J.R. and Civelli O.: J. Biol. Chem. 265, 5825-5832 (1990).
49. Chanda P.K., Minchin M.C.W., Davis A.R., Greenberg L., Reilly Y., McGregor W.H., Bhat R., Lubeck M.D., Mizutani S. and Hung P.P.: Mol. Pharmacol. 43, 516-520 (1993).
50. Andrade R., Malenka R.C. and Nicoll R.A.: Science 234, 1261-1265 (1986).
51. Ho B.Y., Karschin A., Branchek Th., Davidson N. and Lester H.A.: FEBS Lett 312, 259-262 (1992).
52. Kuipers W., Van Wijngaarden I., Kruse C.G., Ter Horst-Van Amstel M., Tulp M.Th.M. and IJzerman A.P.: J. Med. Chem. 38, 1942-1954 (1995).
53. Guan X.-M., Peroutka S.J. and Kobilka B.K.: Mol. Pharmacol. 41, 695-698 (1992).
54. Kuipers W., Link R., Standaar P.J., Stoit A.R., Van Wijngaarden I., Leurs R. and IJzerman A.P.: Mol. Pharmacol. 51, 889-896 (1997).
55. Grånäs Ch., Nordvall G. and Larhammar D.: Eur. J. Pharmacol. 349, 367-375 (1998).
56. Sprang S.R.: Ann. Rev. Biochem. 66, 639-678 (1997).
57. Rens-Domiano S. and Hamm H.E.: FASEB J. 9, 1059-1066 (1995).
58. Gudermann Th., Kalkbrenner F. and Schultz G.: Ann. Rev. Pharmacol. Toxicol. 36, 429-459 (1996).
59. Kjeldgaard M., Nyborg J. and Clark B.F.C.: FASEB J. 10, 1347-1368 (1996).
60. Neer E.J.: Cell 80, 249-257 (1995).
61. Kaziro Y., Itoh H., Kozasa T., Nakafuka M. and Satoh T.: Ann. Rev. Biochem. 60, 349-400 (1991).
62. Varrault A., Le Nguyen D., McClue S., Harris B., Jouin P. and Bockaert J.: J. Biol. Chem. 269, 16720-16725 (1994).
63. Lembo P.M.C., Ghahremani M.H., Morris S.J. and Albert P.R.: Mol. Pharmacol. 52, 164-171 (1997).
64. Medina R., Grishina G., Meloni E.G., Muth Th.R. and Berlot C.H.: J. Biol. Chem. 271, 24720-24727 (1996).
65. Grishina G. and Berlot C.H.: J. Biol. Chem. 272, 20619-20626 (1997).
66. Sunahara R.K., Dessauer C.W. and Gilman A.G.: Ann. Rev. Pharmacol. Toxicol. 36, 461-480 (1996).
67. Taussig R., Tang W.-J., Hepler J.R. and Gilman A.G.: J. Biol. Chem. 269, 6093-6100 (1994).
68. Taussig R. and Gilman A.G.: J. Biol. Chem. 270, 1-4 (1995).
69. Houslay M.D. and Milligan G.: TIBS 22, 217-224 (1997).
70. Skiba N.P. and Hamm H.E.: Nature Struct. Biol. 5, 88-92 (1998).
71. Zimmermann G., Zhou D. and Taussig R.: J. Biol. Chem. 273, 19650-19655 (1998).
72. Varga E.V., Stropova D., Rubenzik M., Wang M., Roeske W.R. and Yamamura H.I.: Eur. J. Pharmacol. 348, R1-R2 (1998).
73. Nelson D.L.: Pharmacol. Biochem. Behav. 40, 1041-1051 (1991).
74. Glennon R.A.: Drug Dev. Res. 26, 251-274 (1992).
75. Cliffe I.A. and Fletcher A.: Drugs Future 7, 631-642 (1993).
76. Boess F.G. and Martin I.L.: Neuropharmacology 33, 275-317 (1994).
77. Fletcher A., Cliffe I.A. and Dourish C.T.: TIPS 14, 441-448 (1993).
78. Van Wijngaarden I., Tulp M.Th.M. and Soudijn W.: Eur. J. Pharmacol. - Mol. Pharmacol. Sect. 188, 301-312 (1990).
79. Liu Y., Yu H., Svensson B.E., Cortizo L., Lewander T. and Hacksell U.: J. Med. Chem. 36, 4221-4229 (1993).
80. Romero A.G., Leiby J.A., McCall R.B., Piercey M.F., Smith M.W. and Han F.: J. Med. Chem. 36, 2066-2074 (1993).
81. Stjernlöf P., Gullme M., Elebring T., Anderson B., Wikström H., Lagerquist S., Svensson K., Ekman A., Carlsson A. and Sundell S.: J. Med. Chem. 36, 2059-2065 (1993).
82. Stjernlöf P., Elebring T., Nilsson J., Andersson B., Lagerkvist S., Svensson K., Ekman A., Carlsson A. and Wikström H.: J. Med. Chem. 37, 3263-3273 (1994).
83. Stjernlof P., Ennis M.D., Hansson L.O., Hoffman R.L., Ghazal N.B., Sundell S., Smith M.W., Svensson K., Carlsson A. and Wikström H.: J. Med. Chem. 38, 2202-2216 (1995).
84. Björk L., Hoök B.B., Nelson D.L., Andén N.E. and Hacksell U.: J. Med. Chem. 32, 779-783 (1989).
85. Naiman N., Lyon R.A., Bullock A.E., Rydelek L.T., Titeler M. and Glennon R.A.: J. Med. Chem. 32, 253-256 (1989).
86. Glennon R. A., Naimann N.A., Pierson M.E., Smith J.D., Ismaiel A.M., Titeler M. and Lyon R.A.: J. Med. Chem. 32, 1921-1926 (1989).
87. Podona T., Guardiola-Lemaitre B., Caignard D.-H., Adam G., Pfeiffer B., Renard P. and Guillaumet G.: J. Med. Chem. 37, 1779-1793 (1994).
88. Hibert M.F., McDermott I., Middlemiss D.N., Mir A.K. and Fozard J.R.: J. Med. Chem. 24, 31-37 (1989).
89. Hillver S.-E., Björk L., Li Y.L., Svensson B., Ross A., Andén N.E. and Hacksell U.: J. Med. Chem. 33, 1541-1544 (1990).
90. Backlund Höök B., Cortizo L., Johansson A.M., Westlind-Danielsson A., Mohell N. and Hacksell U.: J. Med. Chem. 39, 4036-4043 (1996).
91. Johansson L., Sohn D., Thorberg S.-O., Jackson D.M., Kelder D., Larsson L.-G., Rényi L., Ross S.B., Wallsten C., Eriksson H. et al.: J. Pharmacol. Exp. Therap. 283, 216-225 (1997).
92. Liu Y., Mellin C., Bjork L., Svensson B., Csoregh I., Helander A., Kenne L., Andén N.E. and Hacksell U.: J. Med. Chem. 32, 2311-2318 (1989).
93. Mellin C., Vallgårda J., Nelson D.L., Bjork L., Yu H., Andén N.E., Csöregh I., Arvidsson L.E. and Hacksell U.: J. Med. Chem. 34, 497-510 (1991).
94. Liu Y., Yu H., Mohell N., Nordvall G., Lewander T. and Hacksell U.: J. Med. Chem. 38, 150-160 (1995).
95. Lin C.H., Haadsma-Svensson S.R., Lathi R.A., McCall R.B., Piercey M.F., Schreur P.J.K.D., Von Voigtlander P.F., Smith M.W. and Chidester C.G.: J. Med. Chem. 36, 1053-1068 (1993).
96. Chidester C.G., Lin C.-H., Lathi R.A., Haadsma-Svensson S.R. and Smith M.W.: J. Med. Chem. 36, 1301-1315 (1993).
97. Wikström H., Andersson B., Elebring T., Jacyno J., Allinger N.L., Svensson K., Carlsson A. and Sundell S.: J. Med. Chem. 30, 1567-1573 (1987).
98. Lin C.H., Haadsma-Svensson S.R., Philips G., Lathi R.A., McCall R.B., Piercey M.F., Schreur P.J.K.D., Von Voigtlander P.F., Smith M.W. and Chidester C.G.: J. Med. Chem. 36, 1069-1083 (1993).
99. Comoy C., Marot C., Podona T., Baudin M.-L., Morin-Allory L., Guillaumet G., Pfeiffer B., Caignard D.-H., Renard P. et al.: J. Med. Chem. 39, 4285-4298 (1996).
100. Hoyer D. and Schoefter P.: J. Rec. Res. 11, 197-214 (1991).
101. Hoyer D., in: J.R. Fozard (ed.): The peripheral actions of 5-hydroxytryptamine. Oxford University Press, New York 1989, 72-99.
102. Dahlgren T., Dean R.L., Gharat L.A., Johansson A.M., Lambert G., Li H.B., Nelson D.L., Yang Y. and Martin A.R.: Bioorg. Med. Chem. Lett. 5, 2963-2968 (1995).
103. Newman-Tancredi A., Conte C., Chaput C., Verrièle L., Audinot-Bouchez V., Lochon S., Lavielle G. and Millan M.J.: Naunyn-Schmiedeberg's Arch. Pharmacol. 355, 682-688 (1997).
104. Mantegani S., Brambilla E., Caccia C., Damiani G., Fornaretto M.G., McArthur R.A. and Varasi M.: Bioorg. Med. Chem. Lett. 8, 1117-1122 (1998).
105. Slaughter J.L., Harrington M.A. and Peroutka S.J.: Life Sci. 47, 1331-1337 (1990).
106. Foreman M.M., Fuller R.W., Leander J.D., Benvenga M.J., Wong D.T., Nelson D.L., Calligaro D.O., Swanson S.P., Lucot J.B. and Flaugh M.C.: J. Pharmacol. Exp. Therap. 267, 58-71 (1993).
107. Cannon J.G., Mohan P., Bojarski J., Long J.P., Bhatnagar R.K., Leonard P.A., Flynn J.R. and Chatterjee T.K.: J. Med. Chem. 31, 313-318 (1988).
108. Cannon J.G., Moe S.T. and Long J.P.: Chirality 3, 19-23 (1991).
109. Cannon J.G., Flaherty P.T., Ozkutlu U. and Long J.P.: J. Med. Chem. 38, 1841-1845 (1995).
110. Westkaemper R.B. and Glennon R.A.: Pharmacol. Biochem. Behav. 40, 1019-1031 (1991).
111. Hedberg M.H., Johansson A.M., Nordvall G., Yliniemelä A., Li H.B., Martin A.R., Hjörth S., Unelius L., Sundell S. and Hacksell U.: J. Med. Chem. 38, 647-658 (1995).
112. Hedberg M.H., Linnanen T., Jansen J.M., Nordvall G., Hjörth S., Unelius L. and Johansson A.M.: J. Med. Chem. 39, 3503-3513 (1996).
113. Cannon J.G., Jackson H., Long J.P., Leonard P. and Bhatnager R.K.: J. Med. Chem. 32, 1959-1962 (1989).
114. Yocca F.D., Smith D.W., Hyslop D.K. and Maayani S.: Soc. Neurosci. Abstr. 12, 422 (1986).
115. De Vivo M. and Maayani S.: J. Pharmacol. Exp. Ther. 238, 248-253 (1986).
116. Löscher W., Witte U., Fredow G., Traber J. and Glaser T.: Naunyn-Schmiedeberg's Arch. Pharmacol. 342, 271-277 (1990).
117. Hamik A., Oksenberg D., Fischette C. and Peroutka S.J.: Biol. Psychiatry 28, 99-109 (1990).
118. Abou-Gharbia M., Patel U.R., Webb M.B., Moyer J.A., Andree T.H. and Muth E.A.: J. Med. Chem. 31, 1382-1392 (1988).
119. Yocca F.D., Hyslop D.K., Smith D.W. and Maayani S.: Eur. J. Pharmacol. 137, 293-294 (1987).
120. López-Rodríguez M.L., Rosado L., Benhamú B., Morcillo M.J., Sanz A.M., Orensanz L., Beneitez E., Fuentes J.A. and Manzanares J.: J. Med. Chem. 39, 4439-4450 (1996).
121. Beneytez M.E., López-Ródriguez M.L., Rosado M.L., Morcillo M.J., Orensanz L., Fuentes J.A. and Manzanaris J.: Eur. J. Pharmacol. 344, 127-135 (1998).
122. López-Rodríguez M.L., Morcillo M.J., Rovat T.K., Fernández E., Sanz A.M. and Orensanz L.: Bioorg. Med. Chem. Lett. 8, 581-586 (1998).
123. El-Bermawy M., Raghupathi R., Ingher S.P., Teitler M., Maayani S. and Glennon R.A.: Med. Chem. Res. 2, 88-95 (1992).
124. Kuipers W., Kruse C.G., Van Wijngaarden I., Standaar P.J., Tulp M.Th.M., Veldman N., Spek A.L. and IJzerman A.P.: J. Med. Chem. 40, 300-312 (1997).
125. Fletcher A., Bill D.J., Bill S.J., Cliffe I.A., Dover G.M., Foster E.A., Haskins J.T., Jones D., Mansell H.L. and Reilly Y.: Eur. J. Pharmacol. 237, 283-291 (1993).
126. Corradetti R., Laaris N., Hanoun N., Laporte A.M., Le Poul E., Hamon M. and Lanfumey L.: Br. J. Pharmacol. 123, 449-462 (1998).
127. Cliffe I.A., Brightwell C.I., Fletcher A., Forster E.A., Mansell H.L., Mansell Y.R., Routledge C. and White A.C.: J. Med. Chem. 36, 1509-1510 (1993).
128. Mos J., Van Hest A., Van Drimmelen M., Herremans A.H.J. and Olivier B.: Eur. J. Pharmacol. 325, 145-153 (1997).
129. Newman-Tancredi A., Chaput C., Verrièle L. and Millan M.J.: Eur. J. Pharmacol. 307, 107-111 (1996).
130. Van Steen B.J., Van Wijngaarden I., Ronken E. and Soudijn W.: Bioorg. Med. Chem. Lett. 8, 2457-2462 (1998).
131. Colpaert F.C., Koek W., Lehmann J., Rivet J.M., Lejeune F., Canton H., Bervoets K., Millan M.J., Laubie M. and Lavielle G.: Drug Dev. Res. 26, 21-48 (1992).
132. El Ahmad Y., Laurent E., Maillet P., Talab A., Teste J.F., Dokhan R., Tran G. and Ollivier R.: J. Med. Chem. 40, 952-960 (1997).
133. Schoeffter P., Fozard J.R., Stoll A., Siegl H., Seiler M.P. and Hoyer D.: Eur. J. Pharmacol. Mol. Pharmacol. Sect. 244, 251-257 (1993).
134. Lanfumey L., Haj-Dahmane S. and Hamon M.: Eur. J. Pharmacol. 249, 25-35 (1993).
135. Modica M., Santagati M., Russo F., Parotti L., De Gioia L., Selvaggini C., Salmona M. and Mennini T.: J. Med. Chem. 40, 574-585 (1997).
136. Taverne T., Diouf O., Depreux P., Poupart J.H., Lesieur D., Guardiola-Lemaitre B., Renard P., Rettori M.C., Caignard D.H. and Pfeiffer B.: J. Med. Chem. 41, 2010-2018 (1998).
137. Reitz A.B., Baxter E.W., Codd E.E., Davis C.B., Jordan A.D., Maryanoff B.E., Maryanoff C.A., McDonnel M.E., Powel E.T., Renzi M.J. et al.: J. Med. Chem. 41, 1997-2009 (1998).
138. Baxter E.W. and Reitz A.B.: Bioorg. Med. Chem. Lett. 7, 763-768 (1997).
139. Glennon R.A., Naiman N.A., Lyon R.A. and Titeler M.: J. Med. Chem. 37, 1968-1971 (1988).
140. Huff J.R., King S.W., Saari W.S., Springer J.P., Martin G.E. and Williams M.: J. Med. Chem. 28, 945-948 (1985).
141. Matyus P., Varga I., Zára E., Mezei A., Behr A., Simay A., Haider N., Boros S., Bakonyi A., Horváth E. et al.: Bioorg. Med. Chem. Lett. 7, 2857-2862 (1997).
142. Dabire H., Bajjou R., Chaouche-Teyara K., Fournier B., De Nanteuil G., Laubie M., Safar M. and Schmitt H.: Eur. J. Pharmacol. 203, 323-324 (1991).
143. Yasunaga T., Naito R., Kontani T., Tsukamoto S., Nomura T., Yamaguchi T. and Mase T.: J. Med. Chem. 40, 1252-1257 (1997).
144. Yasunaga T., Kimura T., Naito R., Kontani T., Wanibuchi F., Yamashita H., Nomura T., Tsukamoto S., Yamaguchi T. and Mase T.: J. Med. Chem. 41, 2765-2778 (1998).
145. Pierson M.E., Lyon R.A., Titeler M., Kowalski P. and Glennon R.A.: J. Med. Chem. 32, 859-863 (1989).
146. De Vry J., Schohe-Loop R., Heine H.-G., Greuel J.M., Mauler F., Schmidt B., Sommermeyer H. and Glaser T.: J. Pharmacol. Exp. Ther. 284, 1082-1094 (1998).
147. Hibert M. and Moser P.: Drugs Future 15, 159-170 (1990).
148. Matsuda T., Yoshikawa T., Suzuki M., Asano S., Somboonthum P., Takuma K., Nakano Y., Morita T., Nakase Y., Sun Kim H. et al.: Jap. J. Pharmacol. 69, 357-366 (1995).
149. Nikam S.S., Martin A.R. and Nelson D.L.: J. Med. Chem. 31, 1965-1968 (1988).
150. Schoeffter P. and Hoyer D.: Br. J. Pharmacol. 95, 975-985 (1988).
151. Langlois M., Brémont B., Rouselle D. and Gaudy F.: Eur. J. Pharmacol. 244, 77-87 (1993).
152. Prisco S., Cagnotto A., Talone D., De Blasi A., Mennini T. and Esposito E.: J. Pharmacol. Exp. Ther. 265, 739-744 (1993).
153. Hjorth S. and Sharp T.: J. Pharmacol. Exp. Ther. 265, 707-712 (1993).
154. Lejeune F., Rivet J.M., Gobert A., Canton H. and Millan M.J.: Eur. J. Pharmacol. 240, 307-310 (1993).
155. Valgårda J., Appelberg U., Arvidsson L.-E., Hjorth S., Svensson B.E. and Hacksell U.: J. Med. Chem. 39, 1485-1493 (1996).
156. Raymond J.R.: J. Biol. Chem. 277, 14747-14753 (1991).
157. Wilkinson L.D. and Dourish C.T., in: S.J. Peroutka (ed.): Serotonin receptor subtypes, basic and clinical aspects. Wiley-Liss Inc, New York 1991, 147-210.
158. Jacobs B.L.: Life Sci. 19, 777-786 (1976).
159. Berendsen H.H.G., Jenck F. and Broekkamp C.L.E.: Pharmacol. Biochem. Behav. 33, 821-827 (1989).
160. Molewijk H.E., Van der Heyden J.A.M. and Olivier B: Eur J. Neurosci. 214 (Suppl. 2), 121-136 (1989).
161. Berendsen H.H.G., Broekkamp C.L.E. and Van Delft A.M.L.: Eur. J. Pharmacol. 187, 97-10 (1990).
162. Myers R.D. and Lee T.F., in: L.C.H. Wang (ed.): Advances in environmental and comparative physiology, vol. 4. Springer-Verlag, Berlin 1989, 161-203.
163. Goodwin G.M. and Green A.R.: Br. J. Pharmacol. 84, 743-753 (1985).
164. 1A Receptors, Behavioural and Neurochemical Pharmacology. Ellis Horwood Ltd., Chichester, U.K. 1987, 161-176.
165. Millan M.J., Rivet J.M., Canton H., Lejeune F., Gobert A., Widdowson P., Bervoets K., Brocco M. and Peglion J.L.: Eur. J. Pharmacol. 230, 99-102 (1993).
166. Anderson I.M., Cowen P.J., Grahame-Smith D.G.: Psychopharmacology 100, 498-503 (1990).
167. Lesch K.P., Mayer S., Disselkamp-Tietze A., Hoh M., Wiesmann M., Osterheider M. and Schulte H.: Biol. Psychiatry 28, 620-628 (1990).
168. Anderson I.M. and Cowen P.J.: Psychopharmacology 106, 428-432 (1992).
169. Olivier B., Zethof T.J.J., Ronken E. and Van der Heyden J.A.M.: Eur. J. Pharmacol. 342, 177-182 (1998).
170. Seletti B., Benkelfat C., Blier P., Annable L., Gilbert F. and de Montigny C.: Neuropsychopharmacology 13, 93-104 (1995).
171. Bill D.J., Knight M., Forster E.A. and Fletcher A.: Br. J. Pharmacol. 103, 1857-1864 (1991).
172. Levi A.D. and Van de Kar L.D.: Life Sci. 51, 83-94 (1992).
173. Groenink L., Van der Gugten J., Verdouw P.M., Maes R.A.A. and Olivier B.: Eur. J. Pharmacol. 280, 185-193 (1995).
174. Korte S.M., Bouws G.A.H., Koolhaas J.M. and Bohus B.: Physiol Behav. 52, 355-361 (1992).
175. Chaouloff F.: Brain Res. Rev. 18, 1-32 (1993).
176. 1A receptors, stress and anxiety - Neuroendocrine and behavioural interrelationships. PhD Thesis, Utrecht 1996, 1-160.
177. Lesch K.P.: Prog. Neuropsychopharmacol. Biol. Psychiatry 15, 723-733 (1991).
178. Yatham I.N. and Steiner M.: Life Sci. 53, 447-453 (1993).
179. Dourish C.T., Hutson P.H. and Curzon G.: Psychopharmacology 86, 197-204 (1985).
180. Dourish C.T., Hutson P.H. and Curzon G.: Brain Res. Bull. 15, 377-384 (1985).
181. Blundell J.E.: Int. J. Obesity 1, 15-42 (1977).
182. Ahlenius S., Larsson K., Svensson L., Hjorth S., Carlsson A.: Pharmacol. Biochem. Behav. 15, 785-792 (1981).
183. 1A receptors, Behavioral and Neurochemical Pharmacology. Ellis Horwood Ltd., Chichester, U.K. 1987, 106-119.
184. Haensel S.M. and Slob A.K.: Eur. J. Pharmacol. 330, 1-9 (1997).
185. Mos J., Olivier B., Bloetjes K. and Poth M., in: A.K. Slob and M.J. Baum (eds.): Psychoneuroendocrinology of growth and development. Medicom, Bussum 1990, 221-232.
186. Olivier B. and Mos J., in: T. Archer and S. Hansen (eds.): Behavioral biology, neuroendocrine axis. Lawrence Erlbaum Ass, Hillsdale, New Jersey 1991, 207-227.
187. Arnone M., Baroni M., Gai J., Guzzi U., Dexlaux M.R, Keane P.E., Le Fur G. and Soubrié P.: Behav. Pharmacol. 6, 276-282 (1995).
188. 1A receptors, Behavioral and Neurochemical Pharmacology. Ellis Horwood Ltd., Chichester, U.K. 1987, 185-198.
189. Mos J., Van Logten J., Bloetjes K. and Olivier B.: Neurosci. Biobehav. Rev. 15, 505-510 (1991).
190. Ahlenius S. and Larsson K.: J. Neural Transm. 77, 163-170 (1989).
191. Coolen L.M., Olivier B., Peters H.J.P.W. and Veening J.G.: Physiol. Behav. 62, 881-891 (1997).
192. Slangen J.L., in: B. Olivier, J. Mos, J.L. Slangen (eds.): Animal models in psychopharmacology. Birkhäuser Verlag, Basel 1991, 359-379.
193. Glennon R.A.: Pharmacol. Biochem. Behav. 25, 135-139 (1986).
194. Ybema C.E., Slangen J.L., Olivier B. and Mos J.: Behav. Pharmacol. 4, 610-624 (1993).
195. Ybema C.E., Slangen J.L., Olivier B. and Mos J.: Pharmacol. Biochem. Behav. 35, 781-783 (1990).
196. Nader M.A., Hoffman S.M., Gleeson S. and Barrett J.E.: Behav. Pharmacol. 1, 57-67 (1989).
197. Schreiber R., Brocco M., Lefèbvre de Ladonchamps B., Monneyron S. and Millan M.: J. Pharmacol. Exp. Ther. 275, 822-831 (1995).
198. Gommans J., Hijzen T.H., Maes R.A.A., Mos J. and Olivier B.: Eur. J. Pharmacol. 284, 135-140 (1995).
199. Kalkman H.O.: Psychopharmacology 201, 39-42 (1990).
200. Schreiber R. and De Vrij J.: J. Pharmacol. Exp. Ther. 265, 572-579 (1993).
201. Griebel G.: Pharmacol. Ther. 65, 319-395 (1995).
202. Zethoff T.J.J., Heyden van der J.A.M., Tolboom J.T.B.M. and Olivier B.: Physiol. Behav. 55, 109 (1994).
203. Vivian J.A. and Miczek K.A.: Psychopharmacology 104, 187-193 (1991).
204. Rodgers R.J.: Behav. Pharmacol. 8, 477-496 (1997).
205. Miczek K.A., Weerts E.M., Vivian J.A. and Barros H.M.: Psychopharmacology 121, 38-56 (1995).
206. Lister R.G.:Pharmacol. Ther. 46, 321-340 (1990).
207. Willner P. and Muscat R., in: B. Olivier, J. Mos, J.L. Slangen (eds.): Animal models in psychopharmacology. Birkhäuser Verlag, Basel 1991, 183-198.
208. Olivier B. and Van der Heyden J.A.M., in: A. Honig, H.M. van Praag (eds.): Depression, Neurobiological, Psychopathological and Therapeutic Advances. John Wiley & Sons, Chichester 1997, 445-457.
209. De Vry J.M., Schreiber R., Glaser T. and Traber J., in: S.M. Stahl (ed.): Serotonin 1A Receptors in Depression and Anxiety. Raven Press, New York 1992, 55-81.
210. Geller I. and Seifter J.: Psychopharmacology 9, 482-492 (1960).
211. Barrett J.E., in: B. Olivier, J. Mos, J.L. Slangen (eds.): Animal Models in Psychopharmacology. Birkhäuser Verlag, Basel 1991, 37-52.
212. Vogel J.R., Beer B. and Clody D.E.: Psychopharmacology 21, 1-7 (1971).
213. 3 antagonists and benzodiazepines; their comparative behavioural pharmacology. John Wiley and Sons Ltd, Chichester 1991, 59-105.
214. Sanger D.J.: J. Pharmacol. Exp. Ther. 254, 420-426 (1990).
215. Boissier J.R., Simon P. and Aron C.: Eur. J. Pharmacol. 4, 145-151 (1968).
216. Aron C., Simon P. and Boissier J.R.: Neuropharmacologia 10, 459-469 (1971).
217. Cuomo V., Cagiano R., Da Salvia M.A., Maselli M.A., Renna G. and Racagni G.: Life Sci. 43, 485-491 (1988).
218. Walsh R.N. and Cummins R.A.: Psychol. Bull. 83, 482-487 (1976).
219. Hughes R.N.: Psychopharmacology 24, 462-469 (1972).
220. Handley S.L. and Mithani S.: Naunyn-Schmiedeberg's Arch. Pharmacol. 327, 1-5 (1984).
221. File S.E., Andrws N. and Hogg S., in: H.G.M. Westenberg, J.A. Den Boer and D.L. Murphy (eds.): Advances in the Neurobiology of Anxiety Disorders. John Wiley SE Sons Ltd, Chichester 1996, 61-79.
222. Pellow S., Johnston A.L. and File S.E.: J. Pharm. Pharmacol. 39, 917-928 (1987).
223. Critchley M.A.E. and Handley S.L.: Psychopharmacology 93, 502-506 (1987).
224. Moser P.C.: Psychopharmacology 99, 48-53 (1989).
225. Crawley J.N.: Pharmacol. Biochem. Behav. 25, 695-699 (1981).
226. Kilfoil T., Michel A., Montgomery D. and Whiting R.L.: Neuropharmacology 28, 901-905 (1989).
227. Carli M. and Samanin R.: Psychopharmacology 94, 84-91 (1988).
228. Schuurman T., Spencer D.G. and Traber J.: Psychopharmacology 89, S54 (1987).
229. File S.E.: Neuropsychobiology 13, 55-62 (1985).
230. Davis M.: Behav. Neurosci. 100, 814-824 (1986).
231. Joordens R.J.E., Hijzen T.H., Peeters B.W.M.M. and Olivier B.: Psychopharmacology 126, 104-109 (1996).
232. Joordens R.J.E., Hijzen T.H. and Olivier B.: Psychopharmacology 139, 383-390 (1998).
233. Hijzen T.H., Houtzager S.W.J., Joordens R.J.E., Olivier B. and Slangen J.L.: Psychopharmacology 118, 150-154 (1995).
234. Lal H. and Emmett-Oglesby M.W.: Neuropharmacology 22, 1423-1441 (1983).
235. Stephens D.N. and Andrews J.S., in: P. Willner (ed.): Behavioural Models in Psychopharmacoiogy. Cambridge Univ. Press, Cambridge 1991, 50-75.
236. De Vry J., Benz U., Schreiber R. and Traber J.: Eur. J. Pharmacol. 249, 331-339 (1993).
237. Sanchez C.: Behav. Pharmacol. 4, 269-277 (1993).
238. Kaltwasser M.T.: Behav. Brain Res. 43, 133-137 (1991).
239. Vivian J.A. and Miczek K.A.: Psychopharmacology 112, 66-73 (1993).
240. Tornatzky W. and Miczek K.A.: Psychopharmacology 121, 135-144 (1995).
241. Van der Poel A.M., Noach E.J.K. and Miczek K.A.: Psychopharmacology 97, 147-148 (1989).
242. Olivier B., Molewijk H., Groenink L., Joordens R., Zethof T. and Mos J., in: H.G.M. Westenberg, J.A. Den Boer and D.L. Murphy (eds.): Advances in the Neurobiology of Anxiety Disorders. John Wiley & Sons, Chichester 1996, 83-105.
243. Molewijk H.E., Van der Poel A.M., Mos J., Van der Heyden J.A.M. and Olivier B.: Psychopharmacology 117, 32-40 (1995).
244. Treit D., Pinel J.P.J. and Fibiger H.C.: Pharmacol. Biochem. Behav. 15, 619-626 (1981).
245. 3 Antagonists and Benzodiazepines, their Comparative Behavioural Pharmacology. John Wiley & Sons, Chichester 1991, 107-131.
246. Broekkamp C.L., Rijk H.W., Joly-Gelouin D. and Lloyd K.L.: Eur. J. Pharmacol. 126, 223-229 (1986).
247. Broekkamp C.L.E., Berendsen H.H.G., Jenck F. and Van Delft A.M.L.: Psychopathology 22 (Suppl. 1), 2-12 (1989).
248. Kaesermann H.P.: Psychopharmacology 89, 31-37 (1986).
249. Pollard G.T. and Howard J.C.: Psychopharmacology 94, 433-434 (1988).
250. Molewijk H.E., Van der Poel A.M. and Olivier B.: Psychopharmacology 121, 81-90 (1995).
251. Borsini F., Lecci A., Volterra G. and Meli A.: Psychopharmacology 98, 207-211 (1989).
252. Lecci A., Borsini F., Mancinelli A., D'Arranno V., Stasi A., Voltera G. and Meli A.: J. Neural. Transm. 82, 219-230 (1990).
253. Zethof T.J.J., Van der Heyden J.A.M. and Olivier B.: Eur. J. Pharmacol. 294, 125-135 (1995).
254. Van der Heyden J.A.M., Zethof T.J.J. and Olivier B.: Physiol. Behav. 62, 463-470 (1997).
255. Gardner C.R.: Drug Dev. Res. 5, 185-193 (1985).
256. Gardner C.R.: J. Pharmacol. Meth. 14, 181-187 (1985).
257. Winslow J.T. and Insel T.R.: Progr. Neuropsychopharmacol. Biol. Psychiatry 15, 745-757 (1991).
258. Winslow J.T. and Insel T.R.: Psychopharmacology 105, 513-520 (1991).
259. Olivier B., Molewijk H.E., Van der Heyden J.A.M., Van Oorschot R., Ronken E., Mos J. and Miczek K.A.: Neurosci. Biobehav. Rev. 23, 215-227 (1998).
260. Molewijk H.E., Hartog K. and Van der Poel A.M.: Psychopharmacology 128, 28-31 (1996).
261. Miczek K.A. and Vivian J.A.: Psychopharmacology 110, 379-382 (1993).
262. Porsolt R.D., Lenègre A. and McArthur R.A., in: B. Olivier, J. Mos and J.L. Slangen (eds.): Animal Models in Psychopharmacology. Birkhäuser Verlag, Basel 1991, 137-159.
263. Willner P., in: P. Willner (ed.): Behavioural Models in Psychopharmacology, Theoretical, Industrial and Clinical Perspectives. Cambridge Univ. Press, Cambridge 1991, 91-125.
264. Borsini F. and Meli A.: Psychopharmacology 94, 147-160 (1988).
265. Van der Heyden J.A.M., Olivier B. and Zethof T.H.H., in: B. Olivier, J. Mos and J.L. Slangen (eds.): Animal Models in Psychopharmacology. Birkhäuser Verlag, Basel 1991, 211-215.
266. Van der Heyden J.A.M., Molewijk E. and Olivier B.: Psychopharmagology 92, 127-130 (1987).
267. Seiden L.S., Dahms J.L. and Shaughnessy R.A.: Psychopharmacology 86, 55-60 (1985).
268. Willner P. and Papp M., in: P. Skolnick (ed.): Antidepressants, New Pharmacological Strategics. Humana Press, Toronto NJ 1997, 213-234.
269. Cairncross K.D., Cox B., Forster C. and Wren A.F.: J. Pharmacol. Meth. 1, 131-143 (1978).
270. Danysz W., Archer T. and Fowler C., in: P. Willner (ed.): Behavioural Models in Psychopharmacology, Theoretical, Industrial and Clinical Perspectives. Cambridge Univ. Press, Cambridge 1991, 126-156.
271. Panksepp J., Yates G., Ikemoto S. and Nelson E., in: B. Olivier, J. Mos and J.L. Slangen (eds.): Animal Models in Psychopharmacology. Birkhauser Verlag, Basel 1991, 161-181.
272. Pecknold J.C.: CNS Drugs 2, 234-251 (1994).
273. Fulton B. and Brogden R.N.: CNS Drugs 7, 68-88 (1997).
274. Barradell L.B. and Fitton A.: CNS Drugs 5, 147-153 (1996).
275. De Vry J.M.: Drug News Persp. 9, 270-280 (1996).
276. De Vry J.M.: Psychopharmacology 121, 1-16 (1995).
277. Artigas F., Romero L., De Montigny C. and Blier P.: TINS 19, 378-383 (1996).
278. Conners C.K. Jackson D.L., Silva D. and March J.: Psychopharmacol Bull 33, 507 (1997).
279. Geretsegger C., Greimel K.V., Roed I.S. and Keppel Hesselink J.M.: Int. J. Eating Disorders 17, 359-363 (1995).
280. Murasaki M., Mori A., Endo S., Takemasa K. and Hasegawa K.: Rinsho Hyoka 20, 259-293 (1992).
281. Van Harten J., Bradford L.D. and De Koning P.: EP710481. CA 124,33311 2a (1996).
282. 7th Eur. Stroke Conf. (Edinborough): Cerebrovasc. Dis. 8 (Suppl. 4) (1998).
283. Wolff M.C. and Leander J.D.: Eur. J. Pharmacol. 340, 217-220 (1997).
284. Critchley D.J., Wilson K.M.R. and Middlefell V.C.: Brit. J. Pharmac. 112 (Suppl.), Abstract 109P (1994).
285. Ridley R.M., Harder J.A. and Baker H.F.: Neurodegeneration 5, 467-471 (1996).